FilingSEC EDGAR8-K
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
· SEC accepted
StageClinical-stage
Filing content
The company reported a net loss of $23.8 million for the second quarter of 2026, secured $168.3 million in gross proceeds from its IPO, and highlighted progress in its clinical pipeline.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…